EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Clinical trial NCT05150236 · UNKNOWN

Trial details

NCT number: NCT05150236
Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Prostate Cancer Neoplasms by Site Neoplasms Prostatic Disease

Start date: 2022-04-29
Primary completion: 2024-08-31
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.